| Androgen receptor-independent function of FoxA1 in prostate cancer metastasis HJ Jin, JC Zhao, I Ogden, RC Bergan, J Yu Cancer research 73 (12), 3725-3736, 2013 | 152 | 2013 |
| Labeling TiO2 Nanoparticles with Dyes for Optical Fluorescence Microscopy and Determination of TiO2–DNA Nanoconjugate Stability KT Thurn, T Paunesku, A Wu, EMB Brown, B Lai, S Vogt, J Maser, ... Small 5 (11), 1318-1325, 2009 | 140 | 2009 |
| Inhibition of HIF‐1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3‐M cells S Mirzoeva, ND Kim, K Chiu, CA Franzen, RC Bergan, JC Pelling Molecular Carcinogenesis: Published in cooperation with the University of …, 2008 | 131 | 2008 |
| Rapid fabrication of vascularized and innervated cell-laden bone models with biomimetic intrafibrillar collagen mineralization G Thrivikraman, A Athirasala, R Gordon, L Zhang, R Bergan, DR Keene, ... Nature communications 10 (1), 3520, 2019 | 130 | 2019 |
| Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis JM Pavese, SN Krishna, RC Bergan The American journal of clinical nutrition 100, 431S-436S, 2014 | 118 | 2014 |
| Gene expression profiling of renal medullary carcinoma: potential clinical relevance XJ Yang, J Sugimura, MS Tretiakova, K Furge, G Zagaja, M Sokoloff, ... Cancer 100 (5), 976-985, 2004 | 111 | 2004 |
| Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor β-mediated activation of mitogen … L Xu, RC Bergan Molecular pharmacology 70 (3), 869-877, 2006 | 101 | 2006 |
| Renal medullary carcinoma and ABL gene amplification L Simpson, X He, M Pins, X Huang, SC Campbell, XJ Yang, EJ Perlman, ... The Journal of urology 173 (6), 1883-1888, 2005 | 101 | 2005 |
| Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway CS Craft, D Romero, CPH Vary, RC Bergan Oncogene 26 (51), 7240-7250, 2007 | 94 | 2007 |
| Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1 C Rohlff, MV Blagosklonny, E Kyle, A Kesari, I Yi Kim, DJ Zelner, F Hakim, ... The Prostate 37 (1), 51-59, 1998 | 93 | 1998 |
| A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone JN Graff, TM Beer, JJ Alumkal, RE Slottke, WL Redmond, GV Thomas, ... Journal for immunotherapy of cancer 8 (2), 2020 | 90 | 2020 |
| A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience RH Engel, JA Brown, JH Von Roenn, RM O'Regan, R Bergan, S Badve, ... Cancer investigation 25 (8), 733-737, 2007 | 86 | 2007 |
| Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging R Bergan, F Hakim, GN Schwartz, E Kyle, R Cepada, JM Szabo, D Fowler, ... | 86 | 1996 |
| p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion SA Hayes, X Huang, S Kambhampati, LC Platanias, RC Bergan Oncogene 22 (31), 4841-4850, 2003 | 83 | 2003 |
| Endoglin regulates cancer–stromal cell interactions in prostate tumors D Romero, C O'Neill, A Terzic, L Contois, K Young, BA Conley, ... Cancer research 71 (10), 3482-3493, 2011 | 77 | 2011 |
| A Randomized Phase II Presurgical Trial of Transdermal 4-Hydroxytamoxifen Gel versus Oral Tamoxifen in Women with Ductal Carcinoma In Situ of the Breast O Lee, K Page, D Ivancic, I Helenowski, V Parini, ME Sullivan, ... Clinical cancer research 20 (14), 3672-3682, 2014 | 75 | 2014 |
| Inhibition and treatment of prostate cancer metastasis RC Bergan, KA Scheidt US Patent App. 12/250,351, 2009 | 73 | 2009 |
| Blood telomere length attrition and cancer development in the normative aging study cohort L Hou, BT Joyce, T Gao, L Liu, Y Zheng, FJ Penedo, S Liu, W Zhang, ... EBioMedicine 2 (6), 591-596, 2015 | 72 | 2015 |
| Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables NA Dawson, MR Cooper, WD Figg, DJ Headlee, A Thibault, RC Bergan, ... Cancer 76 (3), 453-462, 1995 | 72 | 1995 |
| Bone‐on‐a‐chip: microfluidic technologies and microphysiologic models of bone tissue A Mansoorifar, R Gordon, RC Bergan, LE Bertassoni Advanced functional materials 31 (6), 2006796, 2021 | 68 | 2021 |
